Weekly CFO Buys Highlights: Authentidate Holding Corp., Berry Petroleum Company, BioMimetic Therapeutics Inc., and Reddy Ice Holdings Inc.

Author's Avatar
Apr 06, 2009
According to GuruFocus Insider Data, the largest CFO buys during the past week were Authentidate Holding Corp., Berry Petroleum Company, BioMimetic Therapeutics Inc., and Reddy Ice Holdings Inc.


For the complete list of stocks that bought by their CFOs, go to: Insider Buys.


Authentidate Holding Corp. (ADAT, Financial): CFO & Treasurer William A Marshall Bought 185,000 Shares


CFO & Treasurer of Authentidate Holding Corp. (ADAT) William A Marshall bought 185,000 shares on 03/31/2009 at an average price of $50875. Authentidate Holding Corp. and its subsidiaries are engaged in themanufacture and distribution of document imaging systems the sale of computer systems and related peripheral equipment components and accessories network and internet services and the development and sale of software-based authentication services. Authentidate Holding Corp. has a market cap of $12.4 million; its shares were traded at around $0.3573 with and P/S ratio of 2.1. Authentidate Holding Corp. had an annual average earning growth of 0.4% over the past 10 years.


Authentidate Holding Corp. recently reported fiscal results for its second quarter 2009 ended December 31, 2008. The company announced its total revenues of $1.6 million and a net loss of $2.6 million ($0.07 per diluted share). This is compared to the second quarter last year which included total revenues of $1.7 million and a net loss of $2.3 million ($0.07 per diluted share). Ben Benjamin, President of Authentidate, stated, "Revenue growth slowed during the second quarter of fiscal 2009 as poor economic conditions impacted our results.”


Buy: Director J David Luce bought 250,000 shares of ADAT stock on 03/31/2009 at the average price of $68750; the price of the stock has decreased by 100% since. Buy: Director John J Waters bought 370,000 shares of ADAT stock on 03/31/2009 at the average price of $101750; the price of the stock has decreased by 100% since.


Berry Petroleum Company (BRY, Financial): Exec VP and CFO David D. Wolf Bought 15,000 Shares


Exec VP and CFO of Berry Petroleum Company (BRY) David D Wolf bought 15,000 shares on 03/30/2009 at an average price of $11.78. Berry Petroleum Company is an independent energy company engaged in the production development acquisition exploitation and exploration of crude oil and natural gas. Berry's principal reserves and producing properties are located in Kern Los Angeles and Ventura Counties in California. The company is also investigating several other basins which would establish another core area and provide for additional growth opportunities and diversification of the Company's predominantly heavy oil resource base. Berry Petroleum Company has a market cap of $607.7 million; its shares were traded at around $13.63 with a P/E ratio of 4 and P/S ratio of 0.6. The dividend yield of Berry Petroleum Company stocks is 2.2%. Berry Petroleum Company had an annual average earning growth of 27.6% over the past 10 years. GuruFocus rated Berry Petroleum Company the business predictability rank of 3.5-star.


Buy: Director Ralph B III Busch bought 5,000 shares of BRY stock on 12/17/2008 at the average price of $9.07; the price of the stock has increased by 50.28% since. Buy: Director William E. Jr. Bush bought 2,650 shares of BRY stock on 12/08/2008 at the average price of $7.19; the price of the stock has increased by 89.57% since. Buy: Director Thomas J. Jamieson bought 50,428 shares of BRY stock on 12/04/2008 at the average price of $8.9 and 35,000 shares of BRY stock on 12/05/2008 at the average price of $6.77; the price of the stock has increased by 101.33% since. Buy: Treasurer Steven Wilson bought 3,000 shares of BRY stock on 12/05/2008 at the average price of $6.67; the price of the stock has increased by 104.35% since.


BioMimetic Therapeutics Inc. (BMTI, Financial): CFO Lawrence E Bullock Bought 6,000 Shares


CFO of BioMimetic Therapeutics Inc. (BMTI) Lawrence E Bullock bought 6,000 shares on 04/01/2009 at an average price of $6.8. BioMimetic Therapeutics Inc. has a market cap of $139.5 million; its shares were traded at around $7.45 with a P/E ratio of 27.6 and P/S ratio of 44.3.


BioMimetic Therapeutics Inc. recently reported fiscal results for its fourth quarter 2008 ended December 31, 2008. The company announced its net loss of $12.2 million ($0.65 per diluted share). This is compared to the same quarter last year which included a net loss of $24.6 ($1.37 per diluted share). "The past year has been filled with challenges as we completed enrollment in both our U.S. pivotal trial and EU clinical study with Augment, released promising results in two pilot trials with our second orthopedic product candidate, Augment Injectable, and dealt with issues surrounding auction rate securities," said Dr. Samuel E. Lynch, president and CEO of BioMimetic Therapeutics.


Buy: 10% Owner A/S Novo bought 500 shares of BMTI stock on 11/11/2008 at the average price of $8 and 50,000 shares of BMTI stock on 01/29/2009 at the average price of $9.63; the price of the stock has decreased by 22.64% since. Sell: General Counsel Earl Martin Douglas sold 1,200 shares of BMTI stock on 03/17/2009 at the average price of $8.45; the price of the stock has decreased by 11.83% since.


Reddy Ice Holdings Inc. (FRZ, Financial): Exec. VP, CFO & Secretary Steven J Janusek Bought 4,950 Shares


Exec. VP, CFO & Secretary of Reddy Ice Holdings Inc. (FRZ) Steven J Janusek bought 4,950 shares on 04/03/2009 at an average price of $1.5. Reddy Ice manufactures and distributes packaged ice under the Reddy Ice brand name. Reddy Ice Holdings Inc. has a market cap of $33.2 million; its shares were traded at around $1.5 with a P/E ratio of 6.8 and P/S ratio of 0.1.


Reddy Ice Holdings Inc. recently reported fiscal results for its fourth quarter 2008 ended December 31, 2008. The company announced its total revenues of $57.9 million and a net loss of $0.44 per diluted share. This is compared to the same quarter last year which included total revenues of $64.3 million and a net loss of $0.30 per diluted share. "Our results for the fourth quarter were below our expectations, as the effects of the slowing national economy continued to put pressure on sales volumes and we incurred some significant one time expenses related to the completion of our strategic review and the change in audit firms," commented Gilbert M. Cassagne, the Company's Chief Executive Officer.


Buy: CEO & President Gilbert M. Cassagne bought 19,950 shares of FRZ stock on 04/03/2009 at the average price of $1.5; the price of the stock has decreased by 0% since. Buy: VP-Finance & Treasurer Mark A Steffek bought 16,945 shares of FRZ stock on 03/16/2009 at the average price of $1.48; the price of the stock has increased by 1.35% since. Buy: Director Michael H Rauch bought 2,500 shares of FRZ stock on 03/13/2009 at the average price of $1.4; the price of the stock has increased by 7.14% since. Buy: Senior VP - Central Operations Graham D Davis bought 500 shares of FRZ stock on 12/30/2008 at the average price of $1.5; the price of the stock has decreased by 0% since. Buy: Executive VP & COO Paul D. Smith bought 15,428 shares of FRZ stock on 12/08/2008 at the average price of $1.79 and 10,590 shares of FRZ stock on 12/11/2008 at the average price of $2.18; the price of the stock has decreased by 31.19% since.